GEN ID to Launch Marketing Campaign for Release of Proprietary Software.

HUNTINGTON BEACH, Calif. -- GEN ID Lab Services Inc. ("GEN ID") (OTC:GDLB) announced today that as a prelude to the release of its proprietary software, which is intended to dramatically improve the field of DNA testing of Single Nucleotide Polymorphism ("SNP") cells, it intends to enter into a marketing campaign which will provide the public and the medical community advanced notice of its product launch.

To ensure the success of its marketing campaign and the dissemination of accurate information to the public, GEN ID has retained the services of two Los Angeles-based marketing firms.

The first, Integrated Marketing Network, specializes in B2B (business-to-business) advertising and marketing. Integrated Marketing Network will create visibility with the consumer markets on a daily basis, utilizing the Internet. They will also market the services of GEN ID direct to its existing extensive client base. Integrated Marketing Network's main office is in Los Angeles.

GEN ID has also retained Prominent Advertising, with offices in Los Angeles. Prominent's primary goal and focus will be to target consumers and potential end users directly. They specialize in mass awareness campaigns. Some of Prominent's techniques include placements of billboards near high-traffic roadways and heavily traveled retail outlets. Prominent will also be developing an advertising campaign intended to target the medical community through the placement of ads in medical journals and magazines, as well as the placement of GEN ID's brochures in physicians' office waiting areas. In addition, Prominent will develop a targeted mailing campaign of information packets to hospitals and private practices nationwide.

"We are not only excited that the development of our software is nearing completion, but we are equally enthusiastic that our marketing campaign is about to launch. It is our goal that every consumer becomes aware of the possibility for them to obtain a DNA snapshot at a fraction of the cost, and in much less time than ever before," stated Hector Veron, president of GEN ID. "This will dramatically improve the area of health care by providing doctors and health care practitioners an opportunity to customize treatment programs as never before. With reduced expenses and greatly reduced risks of side effects from the trial-and-error methods currently practiced, doctors will benefit from the use of this product."

GEN ID is preparing to unveil, to the medical community, its proprietary software, which specializes in the expedited analysis of Single Nucleotide Polymorphism (SNP) cells. The results of SNP analysis provide physicians with a more enlightened choice of drugs.

SNP analysis will also provide information on genetic predisposition to various diseases, such as different forms of cancer, cardiovascular abnormalities, dermatological diseases, etc.

Veron continued, "GEN ID will provide physicians with the necessary data which will allow them to personalize treatment options and prescribe individualized therapies specific to a patient's needs. Each and every consumer will soon learn about the benefits of individualized medical care and how it can better their quality of life."

About GEN ID:

GEN ID is in the business of providing SNP testing. SNP stands for Single Nucleotide Polymorphism. An SNP is a small genetic change, or variation, that can occur within a person's DNA sequence. This analysis will provide information on genetic predisposition to various diseases, such as different forms of cancer, cardiovascular abnormalities, dermatological diseases, etc. SNP data also allows predicting pharmacodynamic pattern pertinent to individual drugs for individual patients.

For more information visit the company's Web site: www.Gen-IDLabs.com.

This news release may include "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact included or incorporated herein may constitute forward-looking statements. Although GEN ID believes that the forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct. The forward-looking statements involve risks and uncertainties that may affect GEN ID's operations and financial performance. Among the factors that could cause results to differ materially are those risks discussed in GEN ID's filings with the Securities and Exchange Commission, including our Annual Reports on Form 10-KSB.